Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803863 | 0.89 | CCNC (0.38) | CYP11B2CYP11B1CYP17A1CCNCCDK8 | |
| SCHEMBL15959120 | 0.89 | PDE3B (0.41) | CCNCCDK8MTNR1AMTNR1BPTPN1 | |
| SCHEMBL1804925 | 0.89 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP17A1CCNCCDK8 | |
| SCHEMBL35843129 | 0.88 | MTNR1A (0.44) | MTNR1AMTNR1BPTPN1ALDH1A1PPARG | |
| SCHEMBL1903298 | 0.88 | MTNR1A (0.44) | MTNR1AMTNR1BPTPN1ALDH1A1PPARG | |
| SCHEMBL1815801 | 0.88 | CYP11B2 (0.43) | CYP11B2CYP11B1CYP17A1CCNCCDK8 | |
| SCHEMBL1889329 | 0.88 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP17A1CCNCCDK8 | |
| SCHEMBL1818457 | 0.87 | CYP4F2 (0.46) | CYP11B2CYP11B1CYP17A1CCNCCDK8 | |
| SCHEMBL1906562 | 0.85 | MTNR1A (0.41) | MTNR1AMTNR1BKDM4EPPARG | |
| SCHEMBL1818710 | 0.84 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP17A1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099533-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS | UNIVERSITAT DE VALÈNCIA (ES) | 2026-05-15 | — | — | WO | claimed |
| WO-2016107906-A1 | METHODS FOR INHIBITING MESENCHYMAL PHENOTYPE AFTER EPITHELIAL-TO-MESENCHYMAL TRANSITION | FIBROSTATIN, S.L. (ES) | 2016-07-07 | — | — | WO | claimed |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | UNIVERSITAT DE VALENCIA (ES) | 2016-06-30 | — | — | US | claimed |
| US-9199936-B2 | GPBP inhibition using Q2 peptidomimetics | Fibrostatin Sociedad Limitada (ES) | 2015-12-01 | — | — | US | claimed |
| EP-2496544-B1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN S L (SE) | 2014-08-20 | — | — | EP | claimed |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2014-03-20 | — | — | US | claimed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | claimed |
| WO-2026099533-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS | UNIVERSITAT DE VALÈNCIA (ES) | 2026-05-15 | — | — | WO | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | UNIVERSITAT DE VALÈNCIA (ES) | 2020-01-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2018-06-28 | — | — | US | disclosed |
| WO-2016107906-A1 | METHODS FOR INHIBITING MESENCHYMAL PHENOTYPE AFTER EPITHELIAL-TO-MESENCHYMAL TRANSITION | FIBROSTATIN, S.L. (ES) | 2016-07-07 | — | — | WO | disclosed |
| US-8586776-B2 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2013-11-19 | — | — | US | disclosed |
| EP-2496544-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | Fibrostatin, S.L. (SE) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544083-B2 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885 |
| US-20140080852-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885 |
| US-20160184274-A1 | Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition | VIM, EPCAM, CDH1 | CYP11B2 4800/4885CYP11B1 4835/4885CYP17A1 4359/4885 |
| US-20180179139-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | CYP11B2 2503/4885CYP11B1 2299/4885CYP17A1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.